News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma PledOx® clinical trial application approved

August 1, 2012

PledPharma AB
Company Announcement

PledPharma PledOx® clinical trial application approved

Stockholm, 2012-08-01 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today announced that its PledOx® phase IIb clinical trial application, PLIANT,
was approved by the Swedish Medical Products Agency (MPA). The PLIANT study
will examine the effect of PledOx pre-treatment on the side effects of FOLFOX
in patients with metastatic colorectal cancer. 

Patients will be randomized to receive PledOx in a dose of 2 or 10 µmol/kg, or
placebo. The randomization phase of the study will be preceded by a
dose-escalation phase with the aim of determining PledOx clinical safety,
tolerability and pharmacokinetic and pharmacodynamic properties (effects of the
body on the drug, and of the drug on the body). 

The primary outcome measure will be the change in absolute neutrophil count
(number of white blood cell subtype). Secondary outcomes will include effects
on the occurrence of febrile neutropenia (sign of infection associated with
loss of white blood cell subtype) and sensory neuropathy (pain and discomfort
originating from peripheral nerve affection). 

The estimated enrolment of patients in the randomization phase of the study is
126 (42 in each of the 3 groups). 6-12 patients will be enrolled in the dose
escalation phase. Professor Glimelius, at Uppsala University Hospital, is the
principal investigator. The study will be done at several sites in Europe and
North America. For more details please see 

“We are very happy about the positive assessment of the Swedish MPA. We
continue to be on track with respect to the timelines of the study and expect
to recruit the first patient during the third quarter and present top line
results in the end of 2013. This is a further step towards bringing an
innovative medicine to patients in high need of improved treatment”, says CEO
Jacques Näsström. 

For further information please contact:

Jacques Näsström, CEO, cell: +46 73 713 0979

Erik Kinnman, Investor relations, cell: +46 73 422 1540

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx®, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For more information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10